Bacil Pharma Ltd vs Divi's Laboratories Limited

A side-by-side comparison of Bacil Pharma Ltd (BACILPHARMALTD) and Divi's Laboratories Limited (DIVISLAB) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Divi's Laboratories Limited leads BACILPHARMALTD vs DIVISLAB on 9 of 14 metrics (3 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth· not comparable—
  • Size & financial health03
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

40.10
P/E ratio
94.52
1.05
P/B ratio
14.90
0.00%
Dividend yield
0.32%
₹0.28
EPS
₹96.75

Profitability

DIVISLAB takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

6.21%
Return on equity
15.32%
-0.97%
Return on capital
20.35%
0.00%
EBITDA margin
32.59%
0.00%
Net margin
24.32%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

—
Revenue CAGR (3Y) even
10.78%
—
Profit CAGR (3Y) even
12.09%

Size & financial health

DIVISLAB takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹28 Cr
Market cap
₹2.45L Cr
₹0 Cr
Revenue
₹10,560 Cr
₹0 Cr
Net profit
₹2,568 Cr
0.00
Debt / equity even
0.00
Bacil Pharma Ltd
  • + ["Company has reduced debt.", "Company is almost debt free.", "Stock is trading at 1.12 times its book value"]
  • − ["Though the company is reporting repeated profits, it is not paying out dividend", "Company has a low return on equity of 3.18% over last 3 years."]
Divi's Laboratories Limited
  • + ["Company has been maintaining a healthy dividend payout of 31.0%", "Company is almost debt free."]
  • − ["Stock is trading at 14.60 times its book value", "The company has delivered a poor sales growth of 8.7% over past five years."]
Bacil Pharma Ltd full analysis Divi's Laboratories Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.